We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.15 | 1.10 | 1.20 | 1.15 | 1.15 | 1.15 | 171,930 | 08:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.29 | 1.56M |
Date | Subject | Author | Discuss |
---|---|---|---|
19/2/2018 10:44 | Time to sit up and take notice. Physiomics previously released Interims in March... late March. They've released Interims this time in February for a very good reason. I suspect that reason is there is going to be a load of great newsflow in the coming weeks and Physiomics wanted to get the HISTORIC financials out of the way. The platform is now set for the future and they have given everybody fair warning with this RNS by going into the Industry background and explaining why they are now so well positioned... yes after 15 years ALL of that INVESTMENT of time and money is about to come to fruition Bad luck to sad bitter losers like PWhite and NappyOn, but we are going to reap the dividends of their failed investments | the stigologist | |
19/2/2018 10:24 | Someone taking advantage of the dips to buy 100,000+ | cool hand kev | |
19/2/2018 09:24 | naplion, sounds like you've had a crash course on suposition and conjecture, from your bum-buddy pwhite | minja19 | |
19/2/2018 09:16 | Guys, don't fall into the trap like I did many years ago, this will gradually go down around the 3 to 4 pence range This might turn good long term but at the moment it's well over priced. | naplion | |
19/2/2018 08:45 | zebbo please replace could with will tx | the patient investor | |
19/2/2018 08:43 | Must be well well oversold now! Should move strong now with some good buying pressure and a positive outlook from bod today | margic | |
19/2/2018 08:39 | Bought a few more, we could be going blue today..... GLA | zebbo | |
19/2/2018 08:36 | Best not leave it to long, new CEO, new contracts, first growth / new customers for years. The potential is starting to be unlocked | zebbo | |
19/2/2018 08:19 | Will be a big reversal day here Anyone with a brain who reads the RNS will figure it out I've added The amount of derampers trying to talk it down is indicative of how they have all eyes on this and desperate to get in | the stigologist | |
19/2/2018 08:13 | mm's willing to buy, as many as you want to sell. work it out. | judge grinder | |
19/2/2018 08:12 | Yawn...put another record on.... | bobdown2 | |
19/2/2018 08:10 | The sales are not PIs selling it is the MM shorting the stock down to where they think the next placing price will be. 2p? | pwhite73 | |
19/2/2018 08:10 | Another anti Pyc post from p.white.. Why hang about... This is now about the future and not the past...it's about taking a chance on future deals and revenues and not the formative years...and it looks like the sell on news brigade and mm.s are going to give a cheap entry point. | bobdown2 | |
19/2/2018 08:09 | PWhite is calling himself a mug! He is hanging around here on this board. | icejelly | |
19/2/2018 08:07 | I heard the same statment 5 years ago. | naplion | |
19/2/2018 08:05 | Very positive outlook but its the same positive outlook they've been giving shareholders for the last 15 years. The EUR500k Merck deal represented 60% of funding requirements for the year that tells you they are going to report losses to the full year 30/06/2018. Let's see who is mug enough to be hanging around until then. | pwhite73 | |
19/2/2018 08:00 | All bodes well going forward. | margic | |
19/2/2018 07:59 | Very positive outlook and feels like there a number of major opportunities in the offing | zebbo | |
19/2/2018 07:57 | An industry view We believe that the advent of more powerful computing solutions, including cloud-based technologies and AI and their increasing adoption within the life sciences industry is leading to a resurgence of interest in rational drug design and in the use of modelling more generally in the R&D process. We further believe that there will be increased acceptance of the value of modelling the effects of oncology treatments rather than falling back on more traditional, often heuristic, methods. | the stigologist | |
19/2/2018 07:50 | Knowing how these shares work they'll probably tank! :0) | ciminna | |
19/2/2018 07:44 | WOW read That! Very bullish statement | the stigologist | |
18/2/2018 20:44 | I think that could eclipse the B2B side Rather than just be another string to the bow Also think another B2B deal is in the offing. Either a contract or Service Provider collaboration | the stigologist |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions